vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Shutterstock, Inc. (SSTK). Click either name above to swap in a different company.
Shutterstock, Inc. is the larger business by last-quarter revenue ($220.2M vs $139.2M, roughly 1.6× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -7.3%, a 42.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -12.0%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $25.9M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 1.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Shutterstock, Inc. is an American provider of stock photography, stock footage, stock music, and editing tools; it is headquartered in New York. Founded in 2002 by programmer and photographer Jon Oringer, Shutterstock maintains a library of around 200 million royalty-free stock photos, vector graphics, and illustrations, with around 10 million video clips and music tracks available for licensing. Originally a subscription site only, Shutterstock expanded beyond subscriptions into à la carte p...
ADMA vs SSTK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $220.2M |
| Net Profit | $49.4M | $-16.0M |
| Gross Margin | 63.8% | 55.8% |
| Operating Margin | 45.1% | -1.1% |
| Net Margin | 35.5% | -7.3% |
| Revenue YoY | 18.4% | -12.0% |
| Net Profit YoY | -55.9% | -1021.0% |
| EPS (diluted) | $0.20 | $-0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $220.2M | ||
| Q3 25 | $134.2M | $260.1M | ||
| Q2 25 | $122.0M | $267.0M | ||
| Q1 25 | $114.8M | $242.6M | ||
| Q4 24 | $117.5M | $250.3M | ||
| Q3 24 | $119.8M | $250.6M | ||
| Q2 24 | $107.2M | $220.1M | ||
| Q1 24 | $81.9M | $214.3M |
| Q4 25 | $49.4M | $-16.0M | ||
| Q3 25 | $36.4M | $13.4M | ||
| Q2 25 | $34.2M | $29.4M | ||
| Q1 25 | $26.9M | $18.7M | ||
| Q4 24 | $111.9M | $-1.4M | ||
| Q3 24 | $35.9M | $17.6M | ||
| Q2 24 | $32.1M | $3.6M | ||
| Q1 24 | $17.8M | $16.1M |
| Q4 25 | 63.8% | 55.8% | ||
| Q3 25 | 56.3% | 60.6% | ||
| Q2 25 | 55.1% | 60.3% | ||
| Q1 25 | 53.2% | 58.4% | ||
| Q4 24 | 53.9% | 55.1% | ||
| Q3 24 | 49.8% | 58.3% | ||
| Q2 24 | 53.6% | 58.5% | ||
| Q1 24 | 47.8% | 58.8% |
| Q4 25 | 45.1% | -1.1% | ||
| Q3 25 | 38.0% | 12.5% | ||
| Q2 25 | 35.1% | 13.0% | ||
| Q1 25 | 30.4% | 4.2% | ||
| Q4 24 | 32.6% | 5.3% | ||
| Q3 24 | 33.1% | 7.2% | ||
| Q2 24 | 36.6% | 9.4% | ||
| Q1 24 | 26.7% | 7.8% |
| Q4 25 | 35.5% | -7.3% | ||
| Q3 25 | 27.1% | 5.1% | ||
| Q2 25 | 28.1% | 11.0% | ||
| Q1 25 | 23.4% | 7.7% | ||
| Q4 24 | 95.2% | -0.6% | ||
| Q3 24 | 30.0% | 7.0% | ||
| Q2 24 | 29.9% | 1.6% | ||
| Q1 24 | 21.7% | 7.5% |
| Q4 25 | $0.20 | $-0.47 | ||
| Q3 25 | $0.15 | $0.37 | ||
| Q2 25 | $0.14 | $0.82 | ||
| Q1 25 | $0.11 | $0.53 | ||
| Q4 24 | $0.45 | $-0.04 | ||
| Q3 24 | $0.15 | $0.50 | ||
| Q2 24 | $0.13 | $0.10 | ||
| Q1 24 | $0.08 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $178.2M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $581.0M |
| Total Assets | $624.2M | $1.4B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $178.2M | ||
| Q3 25 | $61.4M | $165.5M | ||
| Q2 25 | $90.3M | $116.4M | ||
| Q1 25 | $71.6M | $112.2M | ||
| Q4 24 | $103.1M | $111.3M | ||
| Q3 24 | $86.7M | $131.4M | ||
| Q2 24 | $88.2M | $74.9M | ||
| Q1 24 | $45.3M | $71.8M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $581.0M | ||
| Q3 25 | $431.2M | $594.4M | ||
| Q2 25 | $398.3M | $586.2M | ||
| Q1 25 | $373.4M | $547.2M | ||
| Q4 24 | $349.0M | $518.4M | ||
| Q3 24 | $231.9M | $522.9M | ||
| Q2 24 | $188.3M | $520.4M | ||
| Q1 24 | $153.7M | $541.3M |
| Q4 25 | $624.2M | $1.4B | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.4B | ||
| Q1 25 | $510.6M | $1.3B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.3B | ||
| Q2 24 | $376.4M | $1.0B | ||
| Q1 24 | $350.9M | $1.0B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $36.2M |
| Free Cash FlowOCF − Capex | $34.6M | $25.9M |
| FCF MarginFCF / Revenue | 24.8% | 11.8% |
| Capex IntensityCapex / Revenue | 0.8% | 4.7% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $123.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $36.2M | ||
| Q3 25 | $13.3M | $78.4M | ||
| Q2 25 | $21.1M | $26.8M | ||
| Q1 25 | $-19.7M | $25.2M | ||
| Q4 24 | $50.2M | $8.0M | ||
| Q3 24 | $25.0M | $-11.6M | ||
| Q2 24 | $45.6M | $28.0M | ||
| Q1 24 | $-2.2M | $8.3M |
| Q4 25 | $34.6M | $25.9M | ||
| Q3 25 | $-1.1M | $68.0M | ||
| Q2 25 | $18.7M | $15.5M | ||
| Q1 25 | $-24.4M | $14.4M | ||
| Q4 24 | $47.5M | $-952.0K | ||
| Q3 24 | $24.0M | $-26.3M | ||
| Q2 24 | $43.6M | $18.9M | ||
| Q1 24 | $-4.6M | $-6.2M |
| Q4 25 | 24.8% | 11.8% | ||
| Q3 25 | -0.8% | 26.1% | ||
| Q2 25 | 15.3% | 5.8% | ||
| Q1 25 | -21.2% | 6.0% | ||
| Q4 24 | 40.4% | -0.4% | ||
| Q3 24 | 20.0% | -10.5% | ||
| Q2 24 | 40.7% | 8.6% | ||
| Q1 24 | -5.6% | -2.9% |
| Q4 25 | 0.8% | 4.7% | ||
| Q3 25 | 10.7% | 4.0% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 4.1% | 4.5% | ||
| Q4 24 | 2.3% | 3.6% | ||
| Q3 24 | 0.9% | 5.9% | ||
| Q2 24 | 1.9% | 4.1% | ||
| Q1 24 | 2.9% | 6.7% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 5.86× | ||
| Q2 25 | 0.62× | 0.91× | ||
| Q1 25 | -0.73× | 1.35× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | -0.66× | ||
| Q2 24 | 1.42× | 7.71× | ||
| Q1 24 | -0.12× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SSTK
Segment breakdown not available.
